Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLA-LSQ
- Development stage
- Unknown
- Lead developer
- Access to Advanced Health Institute
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GLA-LSQ is an investigational vaccine adjuvant system composed of a nanoliposomal formulation that includes two immunological adjuvants: GLA (glucopyranosyl lipid A), a synthetic monophosphoryl lipid A–like molecule and TLR4 agonist, and LSQ, a liposomal formulation of QS-21, a saponin. It is designed to enhance immune responses to co-administered antigens by stimulating both innate and adaptive immunity. GLA-LSQ has been used in clinical trials as an adjuvant for recombinant protein vaccines against diseases such as malaria (notably with rCSP and PAMVAC antigens) and tuberculosis (with ID93 antigen). Preclinical studies have shown robust T-cell immunity and reduced pathogen burden when used with these antigens. The system was developed by the Infectious Disease Research Institute (IDRI), now known as Access to Advanced Health Institute[1][2][4][5][6].
- Other names
- glucopyranosyl lipid adjuvant containing QS21/saponin
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on GLA-LSQ.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLA-LSQ.